Inventor · disambiguated record
Markus Wartmann
Also filed as: WARTMANN MARKUS
9 granted patents·19 pending applications·113 citations·filing 1999–2024
86Inventor score
Top patents by PatentIndex Score
28 records- 0187US6302838B1Cancer treatment with epothilonesNOVARTIS AG·Filed 1999·Granted Oct 16, 2001·86 cites·24 claims
- 0283US7875601B2Cancer treatment with epothilonesNOVARTIS AG·Filed 2006·Granted Jan 25, 2011·5 cites·36 claims
- 0383US7091226B2Cancer treatment with epothilonesNOVARTIS AG·Filed 2005·Granted Aug 15, 2006·2 cites·37 claims
- 0481US6635666B2Cancer treatment with epothilonesNOVARTIS AG·Filed 2001·Granted Oct 21, 2003·13 cites·7 claims
- 0578US10130629B2Pharmaceutical combinationsNOVARTIS AG·Filed 2016·Granted Nov 20, 2018·3 cites·7 claims
- 0676US7612052B2Combinations comprising epothilones and pharmaceutical uses thereofNOVARTIS AG·Filed 2008·Granted Nov 3, 2009·2 cites·9 claims
- 0769US2009191264A1Epothilone compositionsSONNTAG JEAN-CLAUDE·Filed 2009·Application pending·0 cites
- 0868US2024382457A1Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitorsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0962US8008330B2Combinations comprising epothilones and pharmaceutical uses thereofNOVARTIS AG·Filed 2009·Granted Aug 30, 2011·0 cites·3 claims
- 1062US7723339B2Combination comprising a signal transduction inhibitor and an epothilone derivativeNOVARTIS AG·Filed 2002·Granted May 25, 2010·2 cites·10 claims
- 1161US2005042275A1Epothilone compositionsFiled 2004·Application pending·0 cites
- 1260US2009202541A1Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agentBRUNS CHRISTIAN·Filed 2009·Application pending·0 cites
- 1360US2004024033A1Cancer treatment with epothilonesFiled 2003·Application pending·0 cites
- 1459US2009069394A1Cancer treatment with epothilonesDILEA CLIFFORD·Filed 2008·Application pending·0 cites
- 1558US12083101B2Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitorsNOVARTIS AG·Filed 2021·Granted Sep 10, 2024·0 cites·33 claims
- 1653US2010055709A1Tubulin Mutation DiagnosticCULVER KENNETH WAYNE·Filed 2009·Application pending·0 cites
- 1750US2011033458A1Combinations comprising epothilones and pharmaceutical uses thereofHOHNEKER JOHN ARTHUR·Filed 2010·Application pending·0 cites
- 1850US2012283206A1Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.BRUNS CHRISTIAN·Filed 2012·Application pending·0 cites
- 1947US2004167134A1Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agentFiled 2002·Application pending·0 cites
- 2044US2011257206A1Combinations of Therapeutic Agents for Treating CancerBURKE GREGORY·Filed 2011·Application pending·0 cites
- 2144US2010173934A1Combinations of therapeutic agents for treating cancerBURKE GREGORY P·Filed 2007·Application pending·0 cites
- 2243US2008131884A1Tubulin Mutation DiagnosticCULVER KENNETH WAYNE·Filed 2005·Application pending·0 cites
- 2342US2004235796A1Combinations comprising epothilones and pharmaceutical uses thereofFiled 2002·Application pending·0 cites
- 2442US2006235059A1Cancer treatment with epothilonesDILEA CLIFFORD·Filed 2004·Application pending·0 cites
- 2540US2007134744A1Epothilone resistant cell linesATADJA PETER W·Filed 2007·Application pending·0 cites
- 2639US2016095842A1Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancerFRITSCH CHRISTINE·Filed 2014·Application pending·0 cites
- 2735US2004038324A1Epothilone resistant cell linesFiled 2001·Application pending·0 cites
- 2835US2005227300A1Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitorsATADJA PETER W·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Markus Wartmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →